HealthDay News — Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA Network Open.

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The impacts of antihypertensive drugs and blood pressure (BP) on ALS are currently debatable. Objective To evaluate the causal relationship involving antihypertensive drugs, BP, and ALS through a ...

As drug developers turn toward more targeted and mechanism-based approaches, understanding how therapeutics alter transcriptional activity is essential. For potential candidates that act on the ...

Treating coronary artery disease will involve a personalised treatment plan consisting of lifestyle changes and a combination of medications. Learn more here.

The increasing incidence of hypertension, driven by sedentary lifestyles, poor dietary habits, and obesity, is a primary growth factor. The World Health Organization (WHO) estimates that hypertension ...

Antihypertensive medicines can help bring blood pressure back down to a normal range. Find out their names and how they work.

Could a Hypertension Drug Protect Against Post-Stroke Epilepsy? — Observational study suggests one antihypertensive class might be preventive ...

To quantify the mortality and morbidity effects from different first-line antihypertensive drug classes: thiazides (low-dose and high-dose), beta-blockers, calcium channel blockers, ACE inhibitors, ...